Côte d'Ivoire
Tuberculosis profile
| High HIV burden |
Population  2013 20 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 4 (2.5–5.6) 20 (12–28)
Mortality (HIV+TB only) 2.1 (1.6–2.6) 10 (7.8–13)
Prevalence  (includes HIV+TB) 44 (23–70) 215 (115–346)
Incidence  (includes HIV+TB) 35 (32–38) 170 (157–188)
Incidence (HIV+TB only) 8 (7.3–8.9) 39 (36–44)
Case detection, all forms (%) 72 (65–78)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 2.5 (1.1–4.9) 13 (0.2–28)
MDR-TB cases among notified pulmonary
TB cases
460 (200–900) 190 (3–410)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 15 241   953
Pulmonary, clinically diagnosed 3 119   0
Extrapulmonary 5 436   0
       
Total new and relapse 24 749    
Previously treated, excluding relapses 550    
Total cases notified 25 299    
Among 15 241 new cases:
390 (3%) cases aged under 15 years; male:female ratio: 1.7
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 313 (2%) 1 112 (74%) 1 112
Laboratory-confirmed RR-/MDR-TB cases     379
Patients started on MDR-TB treatment     61
TB/HIV 2013 Number (%)
TB patients with known HIV status 22 502 (89)
HIV-positive TB patients 5 506 (24)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 4 245 (77)
HIV-positive TB patients on antiretroviral therapy (ART) 3 030 (55)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New cases registered in 2012 79
Previously treated cases registered in 2012 66
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011  
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 0.6
Culture (per 5 million population) 0.5
Drug susceptibility testing (per 5 million population) 0.5
Sites performing Xpert MTB/RIF 2
Is second-line drug susceptibility testing available? No
Financing TB control 2014  
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-05-24 Data: www.who.int/tb/data